Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial.

Jennifer Sasson,Alexandra N Donlan,Jennie Z Ma,Heather Haughey,Rachael Coleman,Uma Nayak,Amy J Mathers,Patrick E H Jackson,Scott K Heysell,Jeffrey M Sturek,William A Petri

medRxiv : the preprint server for health sciences（2022）

Cited 2|Views5
No score
Abstract
Dupilumab was well tolerated and improved 60-day survival in patients hospitalized with moderate to severe COVID-19. Blockade of type 2 immunity offers promise as a novel treatment for COVID-19.
More
Translated text
Key words
dupilumab,severe covid,hospitalized patients,treatment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined